Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy
Turning Level Therapeutics, Inc. SAN DIEGO, May 10, 2022 (Globe NEWSWIRE) — Turning Stage Therapeutics,…